Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lexeo Therapeutics, Inc.LXEO · Entity 5687 | Chief Financial Officer | September 24, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lexeo Therapeutics, Inc.
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2036-09-23 | Direct | 54,750 |
Reported balance
After 2026-09-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-24 · Grant · Acquired 54,750 · Balance 54,750 F1: 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 21:15 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantStock Option (right to buy) · Derivative | 54,750 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0002083206-26-000009 · form4-09282026_050908.xml · derivative · entry 1 Tamayo Louis Edward · CIK 0002083206 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,750 Underlying: Common Stock · 54,750 shares Expires 2036-09-23 F1 · derivative.exercise_date: 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 21:00 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | SaleCommon Stock | 4,117 | $4.91 | $20,202.53 |
DisclosureSEC source: 0002083206-26-000007 · form4-08192026_050809.xml · nonDerivative · entry 1 Tamayo Louis Edward · CIK 0002083206 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,907 F1 · kind: Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs"). F2 · price: This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Includes 78,415 Restricted Stock Units. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 22:49 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | SaleCommon Stock | 4,641 | $4.49 | $20,838.09 |
DisclosureSEC source: 0002083206-26-000005 · form4-07012026_100733.xml · nonDerivative · entry 2 Tamayo Louis Edward · CIK 0002083206 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,024 F1 · kind: Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs"). F2 · price: This transaction was executed in multiple trades at prices ranging from $4.33 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Includes 89,665 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 22:49 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002083206-26-000005 · form4-07012026_100733.xml · nonDerivative · entry 1 Tamayo Louis Edward · CIK 0002083206 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,665 Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 22:00 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantStock Option (right to buy) · Derivative | 226,665 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0002083206-26-000002 · form4-02062026_050201.xml · derivative · entry 2 Tamayo Louis Edward · CIK 0002083206 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,665 Underlying: Common Stock · 226,665 shares Expires 2036-02-03 F3 · derivative.exercise_date: 25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 22:00 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantCommon Stock | 44,665 | $0.00 | $0.00 |
DisclosureSEC source: 0002083206-26-000002 · form4-02062026_050201.xml · nonDerivative · entry 1 Tamayo Louis Edward · CIK 0002083206 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,665 F1 · shares: The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date. F2 · balance_after: The reported securities are RSUs. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 18:00 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantStock Option (right to buy) · Derivative | 280,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001415889-25-023491 · form4-09032025_020901.xml · derivative · entry 2 Tamayo Louis Edward · CIK 0002083206 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2035-08-28 F3 · derivative.exercise_date: 25% of the shares underlying the option vest and become exercisable on August 15, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 18:00 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023491 · form4-09032025_020901.xml · nonDerivative · entry 1 Tamayo Louis Edward · CIK 0002083206 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 F1 · shares: The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on August 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date. F2 · balance_after: The reported securities are RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.